No definition available.
Acute drug-induced interstitial lung disorder
ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
299 |
4. Check minimum number of eventsNone |
299 |
5. Include endpointsNone |
299 |
6. Filter based on genotype QC (FinnGen only) |
278 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Acute drug-induced interstitial lung disorder
based on the number of shared cases.
Similar with more cases:
- Respiratory conditions due to other external agents
- Lung diseases due to external agents
- Diagnoses used for exclusion with ILD
- Other pulmonary diagnosis
- Excluding asthma or asthma-COPD overlap
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2095 | 1174 | 893 |
| Only index persons | 1591 | 915 | 676 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 71.85 | 72.84 | 70.45 |
| Only index persons | 70.45 | 71.25 | 69.35 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 278 | 141 | 137 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.06 |
| Median age at first event (years) | 68.12 | 65.44 | 70.87 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 282
- Matched controls
- 2820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J70.2
ICD-10 Finland
Acute drug-induced interstitial lung disorders
+∞
307.7
282
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
16.6
100.0
99
89
TGC00
NOMESCO Finland
Bronchial lavation
16.0
60.6
56
43
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.9
42.4
80
154
H02AB06
ATC
prednisolone; systemic
6.5
41.2
225
1066
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
12.8
35.2
36
32
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.2
31.8
82
207
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.9
29.6
36
41
GD1AD
NOMESCO Finland
Thorax CT examination
5.9
27.4
56
114
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.8
26.9
149
647
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
4.4
24.1
74
211
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
5.1
24.1
58
136
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.8
23.8
48
96
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.8
23.3
205
1161
H02AB02
ATC
dexamethasone; systemic
4.2
22.5
73
216
A04AA02
ATC
granisetron; systemic, transdermal
4.8
18.2
46
111
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.6
17.7
70
235
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
5.6
17.7
36
72
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
3.9
17.7
62
192
R50.9
ICD-10 Finland
Fever, unspecified
3.4
16.9
74
265
C01BD01
ATC
amiodarone; systemic
6.5
16.4
28
47
JN4AD
NOMESCO Finland
Body CT examination
3.5
16.1
68
237
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
4.9
15.7
37
84
A03FA01
ATC
metoclopramide; systemic, rectal
2.9
15.5
101
453
C03CA01
ATC
furosemide; systemic
2.7
15.5
150
827
JN4BD
NOMESCO Finland
Extensive body CT
3.5
15.5
62
209
L03AA13
ATC
pegfilgrastim; parenteral
5.0
15.2
35
78
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.9
14.9
35
79
J01MA12
ATC
levofloxacin; systemic
2.9
14.3
88
381
ZXE00
NOMESCO Finland
One hour or less
2.6
14.0
144
806
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.3
13.9
39
102
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
13.6
13
*
L04AX03
ATC
methotrexate; systemic
3.6
13.5
50
159
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
4.4
13.1
35
88
A07EC01
ATC
sulfasalazine; oral, rectal
3.7
12.0
41
123
D70.82
ICD-10 Finland
Drug-induced neutropenia
11.8
11.7
21
19
L04AA13
ATC
[U] leflunomide
9.9
11.7
23
25
A04AA55
ATC
palonosetron, combinations; systemic
5.4
11.7
24
48
XW000
NOMESCO Finland
Bone marrow biopsy
4.5
11.1
28
67
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
10.7
10.7
20
20
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
10.7
10.7
20
20
WZC00
NOMESCO Finland
Treatment plan or consultation
2.3
10.6
123
705
P01BA02
ATC
hydroxychloroquine; oral
3.4
10.3
40
131
WX892
NOMESCO Finland
Monitored bed care
3.6
10.3
36
110
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
3.6
10.1
35
106
M04AA01
ATC
allopurinol; systemic
2.6
10.1
68
303
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
3.8
10.1
33
96
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
5.4
10.0
20
39
L01BA01
ATC
methotrexate; systemic
5.2
10.0
21
43
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
9.8
137
841
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.7
86
436
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
15.8
9.6
15
10
A02BC02
ATC
pantoprazole; systemic
2.5
9.4
217
1624
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
3.4
9.3
35
112
XX3DW
NOMESCO Finland
Time consuming IT work
2.8
9.3
54
223
L03AA14
ATC
lipegfilgrastim; parenteral
8.8
9.2
19
23
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
9.2
75
365
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
16.3
9.1
14
9
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.6
9.1
32
98
TPH07
NOMESCO Finland
Cathetrisation of artery
2.7
8.7
53
223
L04AX01
ATC
azathioprine; systemic
5.0
8.7
19
40
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
6.8
8.7
21
33
WZC30
NOMESCO Finland
Teaching
2.4
8.6
69
332
B01AB10
ATC
tinzaparin; parenteral
2.7
8.6
50
206
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
9.9
8.4
16
17
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.6
8.4
54
234
L88
ICPC
Rheumatoid/seropositive arthritis
4.5
8.3
21
50
L04AB01
ATC
etanercept; parenteral
15.1
8.3
13
9
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.8
8.2
19
42
ZXD05
NOMESCO Finland
Urgent procedure
2.2
8.2
101
580
I50.1
ICD-10 Finland
Left ventricular failure
3.3
8.2
33
110
PEF23
NOMESCO Finland
Thrombendarterectomy of femoral artery
9.3
8.2
16
18
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
10.5
8.1
15
15
ZX108
NOMESCO Finland
Inhalation
34.4
8.1
10
*
ZX120
NOMESCO Finland
Intravenous
2.8
8.0
45
182
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
7.9
50
214
ZXE10
NOMESCO Finland
More than one and less than three hours
2.1
7.8
120
747
NHQ40
NOMESCO Finland
Amputation of toe
7.8
7.8
17
23
I50.0
ICD-10 Finland
Congestive heart failure
2.7
7.7
46
191
PD4CG
NOMESCO Finland
Extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
9.2
7.6
15
17
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.1
7.4
33
117
J70.3
ICD-10 Finland
Chronic drug-induced interstitial lung disorders
+∞
7.3
7
*
WW500
NOMESCO Finland
Blood transfusion
3.8
7.3
23
65
I50.9
ICD-10 Finland
Heart failure, unspecified
2.2
7.3
73
384
NH3EA
NOMESCO Finland
Feet X-ray examination with load
7.6
7.3
16
22
L04AA01
ATC
[U] ciclosporin
16.3
7.3
11
7
N03AX16
ATC
[U] pregabalin
2.1
7.2
81
446
N02AA05
ATC
oxycodone; systemic
2.1
7.1
78
426
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
14.2
6.9
11
8
R06.0
ICD-10 Finland
Dyspnoea
2.0
6.9
104
638
R06AE07
ATC
cetirizine; oral
1.9
6.8
122
794
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.2
6.8
28
95
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.7
6.7
38
154
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
2.8
6.7
35
136
M05BX04
ATC
denosumab; parenteral
3.0
6.7
30
107
L04AD01
ATC
ciclosporin; systemic
9.0
6.6
13
15
JN3AD
NOMESCO Finland
Abdominal CT examination
2.4
6.6
49
226
M01CB01
ATC
sodium aurothiomalate; parenteral
10.4
6.6
12
12
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
3.7
6.6
21
60
A41.9
ICD-10 Finland
Sepsis, unspecified
3.7
6.6
21
60
C07AB07
ATC
bisoprolol; oral
1.9
6.5
172
1264
J01MA02
ATC
ciprofloxacin; systemic
1.9
6.5
131
883
A02BC01
ATC
omeprazole; systemic
2.0
6.4
94
568
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
3.6
6.4
21
61
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
3.5
6.4
22
66
L04AA06
ATC
mycophenolic acid; systemic
8.5
6.4
13
16
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
3.1
6.4
27
93
B01AA03
ATC
warfarin; systemic
2.0
6.3
80
459
WF049
NOMESCO Finland
Radiotherapy of metastasis
3.7
6.3
20
57
PWG00
NOMESCO Finland
Reoperation on peripheral vessels for thrombosis or embolism
+∞
6.3
6
*
WB133
NOMESCO Finland
Very demanding adjuvant cytostatic therapy
+∞
6.3
6
*
D64.9
ICD-10 Finland
Anaemia, unspecified
2.3
6.2
49
233
A04AA01
ATC
ondansetron; systemic, rectal
2.7
6.1
34
136
L01CA04
ATC
vinorelbine; systemic
10.3
6.1
11
11
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
2.5
6.0
39
169
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
55
27
25.06
74.21
1.5
1.6
—
—
—
0
0
57
52
13.49
55.53
1.7
1.6
—
—
—
0
0
62
69
11.24
52.79
1.7
1.5
—
—
—
0
0
59
62
11.77
52.27
1.6
1.5
—
—
—
0
0
48
37
15.43
51.56
1.8
1.3
—
—
—
0
0
64
82
9.80
48.91
1.7
1.5
—
—
—
0
0
65
85
9.64
48.89
1.6
1.5
—
—
—
0
0
49
48
12.14
45.28
1.7
1.6
—
—
—
0
0
45
41
12.87
43.53
1.8
1.4
—
—
—
0
0
51
57
10.70
42.96
1.7
1.6
—
—
—
0
0
34
23
16.67
38.88
1.9
1.3
—
—
—
0
0
39
43
10.36
32.91
2.7
5.1
504.57
135.40
iu/ml
—
7
5
47
66
8.35
32.85
1.6
1.3
—
—
—
0
0
98
343
3.85
24.00
2.6
2.1
—
—
—
0
0
51
108
5.54
23.74
2.5
3.0
—
—
—
0
0
32
15
23.89
22.71
1.8
1.3
—
—
—
0
0
32
16
22.37
22.27
1.8
1.3
—
—
—
0
0
99
365
3.64
22.22
2.5
1.9
—
—
—
0
0
33
19
19.49
21.93
1.8
1.3
—
—
—
0
0
117
484
3.42
21.84
2.7
2.0
—
—
—
0
0
29
37
8.62
21.68
1.1
1.2
—
—
—
0
0
25
7
38.97
20.20
1.2
1.3
—
—
—
0
0
37
69
6.02
19.59
1.6
1.4
—
—
—
0
0
76
257
3.68
19.14
2.8
2.0
344.63
387.28
nmol/l
1.02
76
239
80
298
3.35
17.17
5.2
3.6
—
—
—
0
0
211
1415
2.95
14.34
20.4
9.6
4.43
4.23
e9/l
0.61
202
1233
60
208
3.39
14.25
4.1
2.9
10.12
10.39
g/l
0.12
55
190
21
15
15.02
12.98
1.6
2.1
—
—
—
0
0
81
363
2.73
12.09
6.9
4.9
1.10
1.04
mmol/l
0.70
76
332
23
29
8.53
10.83
2.8
1.5
88.51
89.99
%
0.51
23
29
193
1363
2.32
9.74
12.0
7.2
1.20
1.21
mmol/l
0.43
149
1167
15
10
15.75
9.62
1.3
1.2
—
—
—
0
0
112
644
2.23
9.31
4.0
2.8
6.47
4.33
e6/l
0.65
103
586
178
1231
2.21
9.24
11.9
6.4
1.20
1.21
mmol/l
1.16
172
1120
172
1185
2.16
8.87
7.3
4.7
32.95
35.02
g/l
4.74
165
1118
147
967
2.09
8.41
4.8
3.5
—
—
—
0
0
80
422
2.25
8.03
3.5
2.6
21.38
21.65
%
0.07
74
394
71
357
2.32
7.98
9.1
7.4
1.24
0.88
mmol/l
0.33
58
302
138
912
2.00
7.54
5.0
3.3
2.33
2.36
mmol/l
1.43
129
819
121
764
2.02
7.52
5.0
3.5
0.34
0.54
e6/l
0.71
105
572
81
444
2.16
7.32
3.4
2.6
2.23
2.26
g/l
0.24
75
414
24
72
3.55
7.00
2.5
2.3
130.06
123.20
g/l
0.60
18
55
126
824
1.96
6.94
3.6
2.5
54.46
67.28
u/l
0.90
119
760
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
83
3.35
6.91
3.7
2.5
0.32
0.37
iu/ml
0.34
18
46
18
32
5.93
6.88
1.2
1.8
—
—
—
0
0
178
1314
1.96
6.78
25.9
15.7
1.33
1.29
inr
0.37
164
1102
18
35
5.42
6.44
1.2
1.7
—
—
—
0
0
139
966
1.87
6.16
4.9
3.5
1312.32
1649.01
ng/l
0.78
128
841
90
548
1.94
5.95
3.4
1.7
1.37
1.46
mg/l
0.11
75
436
17
47
3.78
5.57
1.1
1.4
—
—
—
0
0
22
73
3.18
5.51
1.8
1.4
0.02
0.02
iu/ml
—
5
16
13
21
6.43
5.45
1.3
1.0
—
—
—
0
0
16
34
4.92
5.39
1.3
1.3
—
—
—
0
0
17
51
3.48
4.97
1.2
1.4
—
116.67
—
0
6
15
42
3.72
4.83
1.9
1.9
31.73
32.74
pg
0.39
15
42
17
52
3.41
4.83
1.8
1.5
—
—
—
0
0
17
52
3.41
4.83
1.8
1.5
—
—
—
0
0
25
97
2.73
4.78
5.4
3.8
4.43
3.34
ratio
—
10
55
19
63
3.16
4.77
1.1
1.3
—
—
—
0
0
30
128
2.50
4.77
3.5
2.8
4.36
4.28
pmol/l
0.16
24
110
112
774
1.74
4.73
5.6
4.4
0.00
0.01
estimate
0.50
64
277
33
148
2.39
4.72
1.2
1.3
—
—
—
0
0
39
189
2.23
4.68
3.6
3.2
4.92
5.12
kpa
0.83
39
184
26
105
2.63
4.61
5.3
4.1
53.89
32.51
mg/l
0.59
15
91
26
105
2.63
4.61
5.3
4.1
114.11
115.37
mg/l
0.01
15
91
9
11
8.41
4.59
3.3
7.3
—
—
—
0
0
33
151
2.34
4.52
3.8
3.4
2.60
2.01
mmol/l
0.52
24
109
19
66
3.01
4.42
1.1
1.2
—
—
—
0
0
42
215
2.12
4.40
2.3
1.6
—
—
—
0
0
103
707
1.72
4.39
5.5
3.9
0.00
0.11
estimate
0.55
61
245
52
289
1.98
4.37
5.3
3.8
2.27
2.09
mmol/l
0.14
44
243
14
34
4.28
4.27
1.3
1.1
—
—
—
0
0
134
993
1.67
4.26
5.7
4.5
0.00
0.03
estimate
1.05
60
254
68
417
1.83
4.25
9.3
7.0
104.40
104.21
mmol/l
0.11
68
417
143
1085
1.65
4.09
6.4
4.6
34.18
39.55
ng/l
0.31
122
874
94
640
1.70
4.08
3.7
3.0
370.81
356.52
umol/l
0.48
84
545
12
29
4.27
3.75
1.2
1.3
—
—
—
0
0
186
1529
1.64
3.70
10.3
5.1
6.94
6.80
mmol/l
0.50
178
1458
197
1646
1.65
3.64
7.3
5.2
3116.60
629.48
e6/l
—
5
29
219
1884
1.73
3.58
20.5
8.5
79.85
81.48
u/l
0.24
219
1781
147
1150
1.58
3.53
3.1
2.6
—
—
—
0
0
9
18
5.13
3.40
1.2
1.0
—
—
—
0
0
16
60
2.77
3.28
1.1
1.2
—
—
—
0
0
162
1310
1.56
3.27
6.0
4.5
0.00
11.12
estimate
0.80
70
315
163
1329
1.54
3.11
5.9
4.5
0.00
1.06
estimate
0.51
67
286
5
5
10.15
2.99
1.2
1.4
—
—
—
0
0
159
1301
1.51
2.90
5.8
4.4
0.00
0.00
estimate
-0.00
66
306
6
9
6.78
2.88
1.0
1.1
—
—
—
0
0
138
1100
1.50
2.84
3.7
3.0
256.44
131.41
ug/l
1.40
130
1005
205
1788
1.54
2.62
8.3
4.6
19.47
13.67
mm/h
4.46
193
1648
6
11
5.55
2.55
1.2
1.7
—
—
—
0
0
6
11
5.55
2.55
1.2
1.7
—
—
—
0
0
207
1822
1.51
2.42
47.4
23.8
14.57
13.88
%
7.93
207
1813
6
12
5.08
2.41
1.2
1.7
—
—
—
0
0
14
58
2.49
2.41
4.6
2.9
11.36
10.06
pmol/l
0.09
14
58
58
397
1.58
2.36
1.4
1.3
87.16
12.84
u/ml
1.72
19
144
78
571
1.51
2.35
2.1
1.8
465.08
443.57
pmol/l
0.35
63
468
29
165
1.84
2.29
2.8
1.8
—
—
—
0
0
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
6
13
4.69
2.28
1.2
1.7
—
—
—
0
0
9
29
3.17
2.24
1.3
1.7
—
—
—
0
0
9
29
3.17
2.24
1.3
1.7
—
—
—
0
0
9
29
3.17
2.24
1.3
1.7
—
—
—
0
0
8
24
3.40
2.19
1.1
1.1
—
—
—
0
0
16
74
2.23
2.19
1.4
1.2
—
—
—
0
0
15
69
2.24
2.08
1.4
1.2
—
—
—
0
0
7
20
3.56
2.07
4.6
3.9
0.79
1.05
%
—
7
20
16
76
2.17
2.07
1.4
1.2
—
—
—
0
0
10
38
2.69
2.02
2.5
4.4
—
—
—
0
0
138
1150
1.39
2.01
3.5
2.8
—
—
estimate
—
0
0
16
77
2.14
2.01
1.4
1.7
—
—
—
0
0
7
21
3.39
1.97
1.0
1.0
—
—
—
0
0
25
143
1.82
1.96
3.1
1.9
1.46
1.52
g/l
0.13
20
128
93
736
1.39
1.81
2.9
2.2
3.33
3.13
mg/l
0.29
88
628
6
18
3.38
1.75
1.2
1.1
—
—
—
0
0
8
30
2.71
1.73
1.3
1.1
—
—
—
0
0
7
24
2.96
1.73
1.1
1.3
—
—
—
0
0
5
13
3.89
1.72
1.2
1.3
80.00
98.38
u/l
—
5
13
5
13
3.89
1.72
1.2
1.3
36.40
42.85
u/l
—
5
13
38
255
1.57
1.69
4.3
3.1
4.85
4.29
kpa
0.89
38
247
78
978
0.72
1.68
2.1
2.0
1.50
1.31
mmol/l
1.15
61
795
5
15
3.37
1.53
1.0
1.1
—
—
—
0
0
5
16
3.16
1.44
1.4
1.3
—
—
—
0
0
6
22
2.76
1.44
1.3
3.4
322.67
899.86
mg
—
6
22
65
503
1.38
1.42
1.8
1.8
1092.63
1177.96
nmol/l
0.36
49
389
203
2188
0.74
1.40
7.6
7.3
41.81
40.23
mmol/mol
1.48
184
2032
55
711
0.72
1.39
4.3
5.1
21.51
21.61
%
0.01
30
372
72
569
1.36
1.38
4.7
3.1
2.50
2.45
mmol/l
1.20
65
507
5
17
2.97
1.36
1.4
1.3
—
—
—
0
0
211
2258
0.74
1.35
5.7
6.5
2.55
2.57
mmol/l
0.14
191
2057
206
2211
0.75
1.33
5.1
5.6
4.41
4.49
mmol/l
0.41
189
2030
205
2200
0.75
1.31
5.1
5.5
1.42
1.48
mmol/l
1.05
187
2001
5
18
2.81
1.29
1.4
1.2
—
—
—
0
0
5
18
2.81
1.29
1.4
1.2
—
—
—
0
0
22
139
1.63
1.27
6.9
4.1
1.84
1.54
%
0.48
22
133
17
101
1.73
1.23
1.4
1.3
—
—
—
0
0
11
58
1.93
1.13
1.6
1.5
—
—
—
0
0
197
2110
0.78
1.10
4.3
4.6
1.29
1.25
mmol/l
0.41
176
1901
63
508
1.31
1.06
7.0
4.2
885.81
200.80
ng/l
0.50
57
432
5
22
2.29
1.04
1.4
1.2
—
—
—
0
0
55
437
1.32
1.02
1.4
1.3
59.58
37.38
iu/ml
0.48
21
140
39
295
1.37
1.00
1.4
1.5
—
—
—
0
0
0
29
0.00
0.98
0.0
1.0
—
41.80
—
0
19
0
29
0.00
0.98
0.0
1.0
—
589.40
—
0
20
13
77
1.72
0.97
1.1
1.4
261.20
293.06
ug/g
—
5
47
191
1772
1.24
0.93
5.6
4.4
15.26
15.03
pmol/l
0.45
168
1583
38
291
1.35
0.91
5.1
3.0
10.26
8.08
umol/l
0.22
31
259
33
247
1.38
0.90
2.2
2.5
35.18
32.07
u/l
0.16
28
200
18
119
1.55
0.90
9.0
2.0
3.36
3.02
g/l
0.83
18
109
6
30
2.02
0.87
1.0
1.2
—
—
—
0
0
56
459
1.27
0.84
4.9
3.2
0.50
1.14
e6/l
1.90
37
252
8
46
1.76
0.83
2.6
2.1
9.94
10.50
mmol/l
—
8
46
42
519
0.78
0.78
3.5
3.5
0.90
0.81
ug/l
0.25
28
363
125
1127
1.20
0.76
3.3
2.5
81.27
78.91
nmol/l
0.45
114
992
39
310
1.30
0.74
2.9
4.4
10.64
47.72
ug/l
0.83
31
267
235
2251
1.26
0.74
42.3
18.9
25.50
25.77
mg/l
0.05
228
1904
6
109
0.54
0.74
1.5
2.0
—
—
—
0
0
5
25
2.02
0.73
1.4
1.2
—
—
—
0
0
95
841
1.20
0.70
1.7
1.8
18.95
20.97
nmol/l
0.70
83
688
16
110
1.48
0.70
9.9
1.9
10.53
10.56
g/l
0.01
16
99
18
128
1.43
0.67
9.0
2.0
7.19
7.47
g/l
0.33
18
118
18
128
1.43
0.67
9.0
2.0
4.06
3.88
g/l
0.15
18
118
18
128
1.43
0.67
9.0
2.0
3.98
4.20
g/l
0.57
18
118
210
2197
0.83
0.67
41.4
18.8
72.02
74.58
ml/min/173m2
1.03
203
2056
13
86
1.54
0.67
1.6
1.4
1.21
1.16
g/l
0.13
13
86
63
540
1.21
0.65
1.2
1.3
0.63
1.29
u/ml
0.97
15
143
5
29
1.74
0.64
2.0
1.7
0.26
0.82
mmol/l
—
5
29
28
218
1.32
0.63
1.6
1.4
—
—
—
0
0
51
430
1.23
0.62
4.9
3.4
1.42
2.13
e6/l
0.64
32
224
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
214
2224
0.84
0.56
5.7
5.6
6.19
6.09
mmol/l
0.37
188
2022
25
315
0.77
0.55
16.9
8.4
—
—
—
0
0
12
82
1.48
0.55
1.8
1.3
0.23
0.24
g/l
0.10
12
82
22
170
1.32
0.53
3.9
2.8
0.67
0.64
%
0.15
22
170
6
98
0.60
0.53
1.5
1.9
—
—
—
0
0
22
171
1.31
0.51
3.0
2.5
10.08
12.67
nmol/l
0.80
17
150
22
172
1.30
0.50
3.9
2.9
1.09
1.11
%
0.05
22
172
229
2353
0.86
0.42
43.5
22.9
138.89
139.69
mmol/l
3.37
223
2309
81
886
0.88
0.41
5.8
6.1
2.26
2.73
ug/l
0.35
66
783
0
15
0.00
0.41
0.0
1.1
—
1.21
—
0
9
9
68
1.33
0.38
1.9
1.5
—
—
—
0
0
230
2354
0.88
0.34
44.4
23.1
4.02
4.01
mmol/l
0.50
224
2307
100
935
1.11
0.32
4.0
4.1
8.75
10.07
mg/mmol
0.19
60
592
23
194
1.20
0.30
1.9
1.6
1.62
1.67
%
0.17
15
161
25
214
1.18
0.29
6.1
3.8
119.40
86.21
ng/l
0.95
20
182
67
619
1.11
0.27
3.0
2.3
—
—
—
0
0
11
136
0.80
0.23
1.2
1.3
—
45.95
—
0
10
216
2113
1.10
0.23
6.6
5.5
2.06
1.99
mu/l
0.15
195
1895
5
39
1.29
0.23
2.0
1.3
0.78
0.94
g/l
—
5
39
5
42
1.19
0.21
1.6
2.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
11
89
1.25
0.21
1.2
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
6
48
1.26
0.20
2.3
1.5
—
—
—
0
0
11
93
1.19
0.14
1.5
1.2
—
—
—
0
0
12
104
1.16
0.12
2.5
1.9
—
—
—
0
0
122
1192
1.04
0.10
2.2
2.2
93.95
95.81
pmol/l
0.24
67
610
12
106
1.14
0.10
1.0
1.0
—
—
—
0
0
5
45
1.11
0.10
1.8
2.7
108.40
106.00
mmol/l
—
5
45
5
45
1.11
0.10
1.8
2.7
1.23
1.19
mmol/l
—
5
45
55
572
0.95
0.09
6.6
4.8
1.02
1.02
kg/l
0.08
37
399
6
54
1.11
0.09
1.3
2.1
—
—
—
0
0
6
54
1.11
0.09
4.0
4.9
20.92
31.81
mg/l
—
6
40
26
277
0.93
0.08
1.4
1.4
—
—
—
0
0
22
209
1.06
0.04
9.6
2.9
55.18
58.28
ml/min/173m2
0.27
11
85
9
97
0.93
-0.00
1.9
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1363.40
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD | 2.16 [1.79, 2.61] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.097 |
During the follow-up period (1.1.1998 — 31.12.2019), 543 out of 1003 females with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD | 3.019 [2.39, 3.81] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.103 |
During the follow-up period (1.1.1998 — 31.12.2019), 468 out of 739 males with ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD died.
Mortality risk
Mortality risk for people of age
years, who have ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.208% | 0.651% |
| 5 | 1.326% | 4.207% |
| 10 | 3.024% | 10.044% |
| 15 | 5.758% | 18.972% |
| 20 | 10.277% | 30.484% |
Relationships between endpoints
↥Index endpoint: ACUTE_DRUGADVERS_INTERSTITIAL_LUNG_DISORD – Acute drug-induced interstitial lung disorder
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data